Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.41 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580340 | 0.80 | CRHR1 (0.37) | CRHR1DGAT1IKBKB | |
| Cadaverine Tartrate SCHEMBL13685353 | 0.79 | CRHR1 (0.39) | CRHR1DGAT1IKBKB | |
| SCHEMBL2585838 | 0.78 | CRHR1 (0.43) | CRHR1MOGAT2DGAT1 | |
| SCHEMBL13685707 | 0.66 | CLK4 (0.35) | IKBKB | |
| SCHEMBL4775977 | 0.63 | TBK1 (0.38) | CRHR1 | |
| SCHEMBL13685572 | 0.63 | CLK4 (0.34) | IKBKB | |
| SCHEMBL4927106 | 0.62 | ALDH1A1 (0.42) | — | |
| SCHEMBL2586635 | 0.62 | MTOR (0.42) | CRHR1MOGAT2MGAT2 | |
| SCHEMBL3793627 | 0.62 | CRHR1 (0.44) | CRHR1 | |
| Succinic Acid SCHEMBL2584999 | 0.61 | VCP (0.46) | DGAT1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269745-A1 | 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR1A, HTR2A | CRHR1 69/4885MOGAT2 904/4885DGAT1 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.